Atreca, Inc. (BCEL) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock ...

The average one-year price target for Atreca Inc - (NASDAQ:BCEL) has been revised to 10.20 / share. This is an increase of 11.89% from the prior estimate of 9.12 dated July 5, 2023. The price target ...

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. Unfortunately, there are also plenty of examples of share prices declining ...

BCEL is set to produce additional data from a phase 1b trial of its antibody ATRC-101 in multiple solid tumor types. Based on previous data, BCEL has refined the patients it enrolls in the trial, ...

BCEL has improved enrollment rates in its phase 1b ATRC-101 study, with 81 patients enrolled as of May 10, 2023. The company has enough cash to reach the readout from another round of data in the ATRC ...

Atreca, Inc.’s BCEL shares plunged about 37% on Aug 11, 2023, after the company reported structural changes in its business in the second-quarter earnings release, which failed to meet investors’ ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether Atreca, Inc.’s (NASDAQ: BCEL) definitive asset purchase agreement with Immunome, Inc. to sell a ...

SAN CARLOS, Calif., May 14, 2021 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery ...